

Eritrea
Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Eritrea			
2. Grant number(s): 19-ERI-25b-X; 15-ERI-08h-Y/ 18-ERI-08p-Y			
3. Date of Decision Letter: 6 March 2019			
4. Date of the Partnership Framework Agreement: 16 April 2013			
5. Programme title: NVS, IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 5 doses per vial, LIQUID			
8. Programme duration²: 2015 - 2019			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2020 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2018	2019	Total ³
Routine Programme (US\$)	US\$227,567 ⁴	US\$281,000	US\$508,567
10. Vaccine introduction grant:	2015		
	US\$100,000 (disbursed on 28 April 2015)		
11. Product switch grant: Not applicable			
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁵			
Number of vaccines to be purchased with Gavi funds	2015-2018	2019	
IPV Routine Programme (doses)		94,100	
Annual Amounts (US\$)	US\$227,567	US\$281,000	
13. Procurement agency: UNICEF			

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2017 to 2019.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

14. Self-procurement: N/A	
15. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Eritrea is encouraged to contribute to vaccine and/or supply costs for IPV.	
16. Operational support for catch-up campaigns: Not applicable	
17. Additional reporting requirements:	
	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
18. Financial clarifications: N/A	
<p>19. Other conditions: Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Eritrea envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Eritrea.</p>	

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
6 March 2019